GelMEDIX partners with Catalent to advance vision-restoring cell therapies
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
CMOs showed an increasing reluctance to take on debt in 2022
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Company hires life science veteran Jessica Cao to join management team
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Subscribe To Our Newsletter & Stay Updated